Analysts Set Milestone Pharmaceuticals Inc. (NASDAQ:MIST) PT at $6.40

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have received a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $6.40.

A number of research analysts recently commented on MIST shares. Zacks Research raised shares of Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Cantor Fitzgerald started coverage on Milestone Pharmaceuticals in a research note on Thursday, August 20th. They set an “overweight” rating and a $3.00 price objective on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research report on Tuesday, July 14th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Milestone Pharmaceuticals in a research note on Thursday, September 3rd.

Milestone Pharmaceuticals Trading Down 6.4%

MIST stock opened at $0.86 on Monday. The firm has a fifty day moving average price of $1.10 and a 200 day moving average price of $1.38. Milestone Pharmaceuticals has a fifty-two week low of $0.85 and a fifty-two week high of $3.06. The firm has a market cap of $107.32 million, a PE ratio of -1.25 and a beta of 0.98. The company has a debt-to-equity ratio of 3.25, a quick ratio of 7.92 and a current ratio of 8.13.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The company had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.82 million. Sell-side analysts anticipate that Milestone Pharmaceuticals will post -0.84 earnings per share for the current fiscal year.

Institutional Trading of Milestone Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Eaton Financial Holdings Company LLC bought a new position in Milestone Pharmaceuticals during the fourth quarter valued at $26,000. HighTower Advisors LLC raised its stake in shares of Milestone Pharmaceuticals by 100.0% in the second quarter. HighTower Advisors LLC now owns 20,000 shares of the company’s stock valued at $27,000 after acquiring an additional 10,000 shares during the period. Welch & Forbes LLC bought a new stake in shares of Milestone Pharmaceuticals in the 1st quarter worth about $30,000. Bay Rivers Group lifted its holdings in shares of Milestone Pharmaceuticals by 55.9% in the 2nd quarter. Bay Rivers Group now owns 46,633 shares of the company’s stock worth $62,000 after acquiring an additional 16,722 shares during the last quarter. Finally, TRU Independence Asset Management 2 LLC purchased a new position in shares of Milestone Pharmaceuticals during the 4th quarter worth about $202,000. 86.18% of the stock is currently owned by institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on developing therapies for cardiovascular conditions. The company’s lead product is etripamil, a short-acting, non-dihydropyridine calcium channel blocker formulated as a self-administered nasal spray.

Etripamil has been developed primarily for the rapid treatment of paroxysmal supraventricular tachycardia (PSVT), a form of abnormally fast heart rhythm that can begin and end suddenly. Milestone has also evaluated the therapy in other cardiovascular applications, including the potential treatment of angina and related conditions.

Founded in 2012, Milestone is headquartered in Montreal, Quebec, and has conducted clinical development activities in North America.